TB-500

TB-500 Capsules is supplied by Crystal Peptides as a catalogued research material in the following format and strength: capsules, 500mcg per capsule, 60 capsules. This presentation is listed for laboratory research, with identity and composition assessed against documentation for the specific batch.

TB-500 is a thymosin beta-4-related research compound. The supplied reference identifies TB-500 as N-acetyl thymosin-β4(17–23), Ac-LKKTETQ, while noting inconsistent use of the name for related fragments, salt forms and full-length thymosin-β4. The catalogue name alone therefore does not establish the molecular entity present. Sequence, N-terminal acetylation and counter-ion must be confirmed in batch records rather than inferred from literature on similarly named materials.

Chemical properties and registry information

Registry identifiers, molecular formulae and molecular masses for full-length thymosin-β4 must not be assigned to a fragment-based material. Such values are omitted here because the exact molecular form of this capsule batch has not been established by the supplied reference.

Research background and published evidence

Published research

The referenced research background includes analytical identification, LC–HRMS identity and metabolite analysis, and assays involving sequence-confirmed Ac-LKKTETQ. These contexts concern defined research materials, not evidence validating this capsule presentation. Findings involving the acetylated fragment must be distinguished from studies of non-acetylated LKKTETQ and full-length thymosin-β4.

Current scientific understanding

There is no established oral efficacy for TB-500. Research on related peptides does not establish the behaviour of this finished capsule formulation. Interpretation requires attention to the molecular identity, test system, formulation and experimental conditions reported in each publication. The capsule format and labelled content do not establish biological activity, bioavailability or suitability for human or veterinary use.

Formulation note

Published research has mostly used other materials or routes rather than this capsule presentation. Findings from injected or differently formulated material cannot be transferred to this capsules formulation. Differences in peptide identity, excipients and experimental context prevent direct equivalence without formulation-specific evidence. This product is distinct from any nasal TB-500 presentation; Crystal Peptides does not offer nasal TB-500.

Quality and testing

Quality information must be linked to the exact capsule product and lot through a batch-specific CoA. Documentation for another presentation, package size, lot or similarly named peptide is not evidence for this material. The labelled strength is a catalogue specification and must be distinguished from any measured content reported for the batch.

Identity, chromatographic purity, analyte content and excipient composition are separate attributes. A purity result alone does not establish capsule content or confirm every aspect of composition. Only tests documented in a matching report should be described as available; unreported measurements must not be assumed. Review the applicable CoA and SDS together when evaluating this research material.

For research use only by qualified professionals. Not for human or veterinary use. No dosing directions are provided.